✓

<

PTC/SB/08a (08-03)
Approved for use through 97/31/2006, ONE 0851-0231
U.S. Platent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to

			Application Number							
			Filing Date							
		TION DISCLOSU	First Named Inventor Hidea			aki NIIMI				
STATEMENT BY APPLICANT			Art Unit							
(Not for submission under 37 CFR 1.99)		Examiner Name								
				Attorney Doc	Attorney Docket Number			36856.1442		
				U.S.I	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document		Pages,Columns, Relevant Passag Figures Appear			
	1	6359327		2002-03-19	Niimi et al					
If you wisl	h to ac	dd additional U.S. Paten	t citatio	n information pl	ease click	the A	dd button.	Add		
			HSP	ATENT APPLIC	CATION P	IIRI K	CATIONS	Remove		

If you wisl	n to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	of cited Document		Pages,Columns,Lines where Relevant Passages or Releva Figures Appear		
	1									
If you wisl	n to a	dd additional U.S. Publ	ished Ap	plication	citation	n information p	lease click the Ad	d butto	n. Add	Т
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove	_
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4	Publication Date	Name of Patente Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	١,
	1	2002-043103	ЛР		А	2002-02-08				E

Α 2000-09-19

Α 2004-02-26

2

3

2000-256062

2004-63548

JP

JP

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Application Number | Filed State | Filed S

	4	2001-167906	JP	A	2001-06-22						
	5	06-302403	JP	A	1994-10-28						
If you wis	h to a	dd additional Foreig	n Patent Docume	nt citation	information pl	ease click the Add buttor	Add				
			NON-PAT	ENT LITI	ERATURE DO	CUMENTS	Remove				
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), ittle of the article (when appropriate), ittle of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher. dr. yet.									
	1	International Searc December 21, 200-		e corresp	onding Internatio	nal Application No. PCT/JP	2004/013316, mailed on	Z			
If you wis	h to a	dd additional non-p	atent literature doc	ument ci	tation informati	on please click the Add t	outton Add	_			
				XAMINE	R SIGNATUR	E					
Examiner	Signa	ture				Date Considered					
*EVALUE	ED. I-	W-1 W4					Daniella a Manager				

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Code of USPTO Petent Documents at twee USPTO_GDUx or MPEP 60104. I Enter office that issued the document, by the In-celetor code (WIPO Standard ST.3). I "See Uppassee painted counters, the exclusion of the year of the register or many preceded the seath number of the pather comment. We will not on the Counter of the pather comment preceded the seath number of the pather comment. "A find of document by the appropriate symbols as exclusion of the Counter of the pather comment." A find of document by the appropriate symbols as exclusive on the document under WIPO Standard ST.16 if possible. "Applicant is to place a check mark there if English insignate precision in satisfacted."

Application Number Fling Date Fling Date Fling Date Fling Date Fling Date Fling Managed Inventor | Hideals NIIMI Art Unit Examiner Name | Attorney Docket Number | 39856.1442

CERTIFICATION STATEMENT

Please see	37	CFR 1	97	and	1.98	to make	the	appropriate se	lection(s)

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 197(eV1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, to keep of item of information disclosure statement was known to any individual designated in 37 CFR 1/5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/7(4)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Christopher A. Bennett #46,710/	Date (YYYY-MM-DD)	2006-04-27
Name/Print	Christopher A. Bennett	Registration Number	4671D

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2044 and 2046. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.